Novo Nordisk A/S saw a price increase of 3.23%, reaching a 20-day high, amid positive market conditions with the Nasdaq-100 up 0.42% and the S&P 500 up 0.19%.
This surge is attributed to Novo Nordisk's recent victory in a patent case for semaglutide in China, which strengthens the company's position in the market and enhances its growth potential. The Supreme People's Court's ruling is viewed as a significant endorsement of medical innovation, expected to encourage further investment in the sector. Despite anticipated challenges from patent expirations in other regions, the ruling does not alter the company's sales forecasts, indicating stability in its market outlook.
The implications of this ruling are substantial, as it not only solidifies Novo Nordisk's leadership in diabetes and obesity treatment but also reflects a supportive regulatory environment that could attract more foreign investment in the Chinese pharmaceutical market.
Wall Street analysts forecast NVO stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for NVO is 54.67 USD with a low forecast of 42.00 USD and a high forecast of 70.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
Wall Street analysts forecast NVO stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for NVO is 54.67 USD with a low forecast of 42.00 USD and a high forecast of 70.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
3 Hold
1 Sell
Moderate Buy
Current: 62.890
Low
42.00
Averages
54.67
High
70.00
Current: 62.890
Low
42.00
Averages
54.67
High
70.00
Citi
Neutral
initiated
DKK 400
2026-01-27
New
Reason
Citi
Price Target
DKK 400
AI Analysis
2026-01-27
New
initiated
Neutral
Reason
Citi initiated coverage of Novo Nordisk with a Neutral rating and DKK 400 price target. The firm views the stock's valuation as appropriate at current share levels.
Goldman Sachs
Buy
maintain
2026-01-22
Reason
Goldman Sachs
Price Target
2026-01-22
maintain
Buy
Reason
Goldman Sachs raised the firm's price target on Novo Nordisk to DKK 436 from DKK 352 and keeps a Buy rating on the shares. The firm believes investor focus in the first half of 2026 will be the launch for Novo's Wegovy pill. The weight loss pill should contribute to positive earnings momentum in the near term, the analyst tells investors in a research note.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for NVO
Unlock Now
CICC
initiated
$73.50
2026-01-08
Reason
CICC
Price Target
$73.50
2026-01-08
initiated
Reason
CICC initiated coverage of Novo Nordisk with an Outperform rating and $73.50 price target.
Barclays
Equal Weight
downgrade
2026-01-06
Reason
Barclays
Price Target
2026-01-06
downgrade
Equal Weight
Reason
Barclays lowered the firm's price target on Novo Nordisk to DKK 360 from DKK 375 and keeps an Equal Weight rating on the shares.
About NVO
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
